Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis

Status Completed

Clinical Trial Summary

Leishmaniasis with diverse clinical manifestations is caused by different species of Leishmania and is endemic in many countries. Although Cutaneous Leishmaniasis (CL) is a self-healing disease, but it takes a long time to heal. Pentavalent antimonials are still the first-line treatment of CL which needs multiple injections, are painful and as such not tolerated by most of the patients, in addition available treatments are not always effective and resistance is reported. Paromomycin sulfate (PM) reported to show anti-Leishmania activity against both CL and visceral leishmaniasis (VL) since 1960s. Therapeutic strategy with high efficacy is urgently needed especially for Anthroponotic Cutaneous Leishmaniasis (ACL). Liposomes are lipid bilayer molecules which entrap water-soluble molecules in their internal water compartment and water-insoluble ones into their lipid bilayers. Liposomes, in proper formulations and sizes, deliver drugs to the skin based on the similarity of the bilayers structure of lipid vesicles to that of natural membrane and target the macrophages within dermis. Several lipid-based formulations have been developed to treat experimental leishmaniasis. Recently different doses of liposomal formulation of PM and liposomal formulation of Glucantime were prepared and showed high efficacy in vivo against L. major infection in BALB/c mice.

In this study the efficacy of liposomal formulation of PM or liposomal formulation of Glucantime in combination with systemic Glucantime in the treatment of ACL parasitologically proven patients will be evaluated. The clinical trial will be carried out according to the International approved GCP (Good Clinical Practice) guide lines.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01050777
Study type	Interventional
Source	Tehran University of Medical Sciences
Contact
Status	Completed
Phase	Phase 0
Start date	March 2011
Completion date	March 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01988909` - WR 279,396 for the Treatment of Cutaneous Leishmaniasis	Phase 2
Enrolling by invitation	`NCT00840359` - Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis	Phase 2
Enrolling by invitation	`NCT00737386` - Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank	N/A
Completed	`NCT00233545` - Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia	Phase 2
Completed	`NCT01462500` - Pharmacokinetics of Miltefosine in Children and Adults	Phase 4
Completed	`NCT01011309` - A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis	Phase 2
Completed	`NCT01301924` - Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis	Phase 2/Phase 3
Not yet recruiting	`NCT02281669` - Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients	N/A
Completed	`NCT01464242` - Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis	Phase 2/Phase 3
Completed	`NCT01790659` - Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama	Phase 3
Completed	`NCT01050907` - Miltefosine to Treat Mucocutaneous Leishmaniasis	Phase 2
Completed	`NCT04340128` - Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)	Phase 3
Terminated	`NCT00317629` - Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis	Phase 3
Completed	`NCT00351520` - Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica	Phase 3
Completed	`NCT01381055` - Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis	Phase 2/Phase 3
Completed	`NCT01380314` - Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis	Phase 2
Terminated	`NCT01380301` - Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony	Phase 2
Completed	`NCT00703924` - Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World	Phase 2
Completed	`NCT00344084` - Surveillance for Leishmaniasis Skin Lesions in Mali
Completed	`NCT03023111` - Miltefosine and GM-CSF in Cutaneous Leishmaniasis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.